+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Vildagliptin"

Vildagliptin API Market - Global Forecast to 2030 - Product Thumbnail Image

Vildagliptin API Market - Global Forecast to 2030

  • Report
  • August 2025
  • 182 Pages
  • Global
From
Oral Antidiabetic Drugs Market Report 2025 - Product Thumbnail Image

Oral Antidiabetic Drugs Market Report 2025

  • Report
  • October 2025
  • 250 Pages
  • Global
From
Oral Anti-Diabetic Drugs - Global Strategic Business Report - Product Thumbnail Image

Oral Anti-Diabetic Drugs - Global Strategic Business Report

  • Report
  • October 2025
  • 197 Pages
  • Global
From
Incretin-Based Drugs Global Market Report 2025 - Product Thumbnail Image

Incretin-Based Drugs Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

Vildagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the amount of incretin hormones in the body. This helps to reduce blood sugar levels in people with type 2 diabetes. Vildagliptin is usually taken in combination with other diabetes medications, such as metformin or a sulfonylurea. It is also used to treat non-alcoholic fatty liver disease (NAFLD). Vildagliptin is available in tablet form and is taken orally. It is generally well tolerated, with the most common side effects being nausea, diarrhea, and headache. It is important to note that vildagliptin can interact with other medications, so it is important to discuss all medications with a healthcare provider before taking vildagliptin. Vildagliptin is marketed by several companies, including Novartis, Merck, and Boehringer Ingelheim. It is also available in generic form from several generic drug manufacturers. Show Less Read more